• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

骨质疏松症治疗趋势对骨折发生率的影响。

The Effects of Trends in Osteoporosis Treatment on the Incidence of Fractures.

作者信息

Horikawa Akira, Miyakoshi Naohisa, Hongo Michio, Kasukawa Yuji, Shimada Yoichi, Kodama Hiroyuki, Sano Akihisa

机构信息

Shizuoka Tokusyukai Hospital, 1-11 Surugaku-Simokawahara-Minami, Shizuoka 421-0117, Japan.

Department of Orthopedic Surgery, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan.

出版信息

J Osteoporos. 2021 May 27;2021:5517247. doi: 10.1155/2021/5517247. eCollection 2021.

DOI:10.1155/2021/5517247
PMID:34136117
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8177999/
Abstract

OBJECTIVE

This study focused on the trends in antiosteoporosis drug preferences and compared the incidence of fractures between patients treated orally and those who were exposed to an awareness campaign and assigned to intravenous/subcutaneous treatment.

METHODS

Our hospital registry included 1,716 osteoporotic women who were over 65 years of age without preexisting vertebral and nonvertebral fractures over 1 year before this study, with bone mineral density (BMD) < -2.5 standard deviation (SD) and fracture assessment tool (FRAX) score > 20%, who were given 1,337 oral and 379 intravenous/subcutaneous prescriptions to treat their osteoporosis. Self-administered surveys (2012, 2013, 2014, 2015, and 2016) collected data on trends of preferences among nine drugs and fracture prevention using relative risk reduction (RRR).

RESULTS

The number of patients taking oral prescriptions decreased gradually from 2012 to 2016, while the number of patients treated with intravenous and subcutaneous injections increased. The incidence of fracture was lower in patients receiving intravenous and subcutaneous injections than in patients taking oral medications.

CONCLUSION

These findings indicate a decrease in oral prescriptions for osteoporosis treatment and that treatment for osteoporosis using intravenous or subcutaneous injections of antiosteoporosis drugs is more effective for preventing fractures.

摘要

目的

本研究聚焦于抗骨质疏松药物偏好趋势，并比较口服治疗患者与接受宣传活动并被指定接受静脉/皮下治疗患者之间的骨折发生率。

方法

我们的医院登记册纳入了1716名65岁以上的骨质疏松女性，她们在本研究前1年无既往椎体和非椎体骨折，骨密度（BMD）< -2.5标准差（SD）且骨折评估工具（FRAX）评分> 20%，这些患者接受了1337份口服和379份静脉/皮下处方来治疗骨质疏松症。自行填写的调查问卷（2012年、2013年、2014年、2015年和2016年）收集了关于九种药物偏好趋势以及使用相对风险降低率（RRR）预防骨折的数据。

结果

从2012年到2016年，口服处方患者数量逐渐减少，而接受静脉和皮下注射治疗的患者数量增加。接受静脉和皮下注射的患者骨折发生率低于口服药物的患者。

结论

这些发现表明骨质疏松症治疗的口服处方减少，并且使用抗骨质疏松药物进行静脉或皮下注射治疗在预防骨折方面更有效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/275f/8177999/6723dce80a0d/jos2021-5517247.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/275f/8177999/ff199fd1d5c8/jos2021-5517247.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/275f/8177999/2d5c0a5bb5c2/jos2021-5517247.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/275f/8177999/200b58e90388/jos2021-5517247.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/275f/8177999/2cb375238c9e/jos2021-5517247.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/275f/8177999/6723dce80a0d/jos2021-5517247.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/275f/8177999/ff199fd1d5c8/jos2021-5517247.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/275f/8177999/2d5c0a5bb5c2/jos2021-5517247.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/275f/8177999/200b58e90388/jos2021-5517247.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/275f/8177999/2cb375238c9e/jos2021-5517247.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/275f/8177999/6723dce80a0d/jos2021-5517247.005.jpg

相似文献

1
The Effects of Trends in Osteoporosis Treatment on the Incidence of Fractures.骨质疏松症治疗趋势对骨折发生率的影响。
J Osteoporos. 2021 May 27;2021:5517247. doi: 10.1155/2021/5517247. eCollection 2021.
2
Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.安大略省双能X线吸收法骨密度测定的应用：基于证据的分析。
Ont Health Technol Assess Ser. 2006;6(20):1-180. Epub 2006 Nov 1.
3
Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.美国医疗保健研究与质量局（AHRQ）对低骨密度或骨质疏松症男性和女性预防骨折治疗的比较效果评价总结：2007年报告更新版
J Manag Care Pharm. 2012 May;18(4 Suppl B):S1-15; discussion S13. doi: 10.18553/jmcp.2012.18.s4-b.1.
4
Vertebral fracture: epidemiology, impact and use of DXA vertebral fracture assessment in fracture liaison services.椎体骨折：流行病学、骨折联络服务中 DXA 椎体骨折评估的影响及应用。
Osteoporos Int. 2021 Mar;32(3):399-411. doi: 10.1007/s00198-020-05804-3. Epub 2021 Jan 21.
5
Clinical risk factor status in patients with vertebral fracture but normal bone mineral density.椎体骨折但骨密度正常患者的临床危险因素状况。
Spine J. 2022 Oct;22(10):1634-1641. doi: 10.1016/j.spinee.2022.05.019. Epub 2022 Jun 6.
6
Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial.阿仑膦酸钠对 FRAX 评分和股骨颈骨密度降低骨折的影响：骨折干预试验。
J Bone Miner Res. 2012 Aug;27(8):1804-10. doi: 10.1002/jbmr.1625.
7
Osteoporosis treatment considerations based upon fracture history, fracture risk assessment, vertebral fracture assessment, and bone density in Canada.基于骨折史、骨折风险评估、椎体骨折评估以及加拿大的骨密度对骨质疏松症的治疗考虑。
Arch Osteoporos. 2020 Jun 23;15(1):93. doi: 10.1007/s11657-020-00775-8.
8
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.阿巴洛肽与安慰剂对绝经后骨质疏松症妇女新发椎体骨折的影响：一项随机临床试验。
JAMA. 2016 Aug 16;316(7):722-33. doi: 10.1001/jama.2016.11136.
9
Bisphosphonates for steroid-induced osteoporosis.双膦酸盐用于治疗类固醇诱导的骨质疏松症。
Cochrane Database Syst Rev. 2016 Oct 5;10(10):CD001347. doi: 10.1002/14651858.CD001347.pub2.
10
Validation of three tools for identifying painful new osteoporotic vertebral fractures in older Chinese men: bone mineral density, Osteoporosis Self-Assessment Tool for Asians, and fracture risk assessment tool.三种用于识别中国老年男性疼痛性新发骨质疏松性椎体骨折工具的验证：骨密度、亚洲人骨质疏松自我评估工具和骨折风险评估工具。
Clin Interv Aging. 2016 Apr 22;11:461-9. doi: 10.2147/CIA.S101078. eCollection 2016.

引用本文的文献

1
Twenty-Year Trends in Osteoporosis Treatment and Post-Fracture Care in South Korea: A Nationwide Study.韩国骨质疏松症治疗与骨折后护理的二十年趋势：一项全国性研究。
J Bone Metab. 2025 Feb;32(1):57-66. doi: 10.11005/jbm.24.829. Epub 2025 Feb 28.
2
The Effects of Switch Therapy in Osteoporosis Treatment after Romosozumab after Comparing with Prior Treatment.与先前治疗相比，罗莫佐单抗治疗后转换疗法在骨质疏松症治疗中的效果。
J Osteoporos. 2024 Jan 9;2024:2144527. doi: 10.1155/2024/2144527. eCollection 2024.

本文引用的文献

1
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.罗莫佐单抗或阿仑膦酸钠用于预防骨质疏松症女性骨折。
N Engl J Med. 2017 Oct 12;377(15):1417-1427. doi: 10.1056/NEJMoa1708322. Epub 2017 Sep 11.
2
Zoledronic Acid (Reclast, Aclasta): A Review in Osteoporosis.唑来膦酸（择泰、艾朗）：骨质疏松症的治疗药物评价。
Drugs. 2016 Nov;76(17):1683-1697. doi: 10.1007/s40265-016-0662-4.
3
Anti-osteoporotic treatments in France: initiation, persistence and switches over 6 years of follow-up.法国的抗骨质疏松治疗：6年随访期间的起始、持续情况及转换情况
Osteoporos Int. 2017 Mar;28(3):853-862. doi: 10.1007/s00198-016-3789-y. Epub 2016 Oct 20.
4
Comparative Efficacy of Bisphosphonates to Prevent Fracture in Men with Osteoporosis: A Systematic Review with Network Meta-Analyses.双膦酸盐预防男性骨质疏松症骨折的比较疗效：一项网状Meta分析的系统评价
Rheumatol Ther. 2016 Jun;3(1):117-128. doi: 10.1007/s40744-016-0030-6. Epub 2016 Apr 22.
5
Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study).唑来膦酸每年一次给药对日本原发性骨质疏松症患者的疗效和安全性：一项随机安慰剂对照双盲研究的两年结果（唑来膦酸治疗骨质疏松症的疗效；ZONE研究）
Osteoporos Int. 2017 Jan;28(1):389-398. doi: 10.1007/s00198-016-3736-y. Epub 2016 Sep 8.
6
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.长期双膦酸盐治疗患者的骨质疏松管理：美国骨与矿物质研究学会特别工作组报告
J Bone Miner Res. 2016 Jan;31(1):16-35. doi: 10.1002/jbmr.2708.
7
Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis.男性骨质疏松症八种治疗药物腰椎骨密度及骨折率比较：网状Meta分析
PLoS One. 2015 May 26;10(5):e0128032. doi: 10.1371/journal.pone.0128032. eCollection 2015.
8
Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.特立帕肽、地诺单抗和口服双膦酸盐预防绝经后骨质疏松症女性椎体和非椎体骨折的间接比较
Menopause. 2015 Sep;22(9):1021-5. doi: 10.1097/GME.0000000000000466.
9
Concern and risk perception: effects on osteoprotective behaviour.担忧与风险认知：对骨保护行为的影响。
J Osteoporos. 2014;2014:142546. doi: 10.1155/2014/142546. Epub 2014 Sep 8.
10
Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review.药物治疗预防骨折的效果比较：一项更新的系统评价。
Ann Intern Med. 2014 Nov 18;161(10):711-23. doi: 10.7326/M14-0317.